Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

被引：0
作者：
Amir T. Fathi
Yi-Bin Chen
机构：
[1] Massachusetts General Hospital,Center for Leukemia
[2] Massachusetts General Hospital,Bone Marrow Transplant Unit, Cox 108
来源：
Current Hematologic Malignancy Reports | 2014年 / 9卷
关键词：
Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Relapse; Graft-vs.-host disease (GVHD); Emerging therapies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Disease relapse remains a major cause of mortality for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Historically, patients who experience disease relapse after HSCT have a dismal prognosis with very few long-term survivors. There is no standard treatment for patients in this situation given the variability in patient characteristics, disease biology, complications such as graft-vs.-host disease (GVHD) and infections, donor availability, and patient choice. Here, we discuss the current options for treatment of relapsed AML after HSCT including conventional chemotherapy, novel agents, donor leukocyte infusion, second allogeneic HSCT, and emerging therapies.
引用
收藏
页码：186 / 192
页数：6
相关论文
共 198 条
[1]  
Gooley TA(2010)Reduced mortality after allogeneic hematopoietic-cell transplantation N Engl J Med 363 2091-2101
[2]  
Chien JW(2008)Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors Leukemia 22 31-41
[3]  
Pergam SA(2012)Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant Blood 119 1972-1980
[4]  
Chen YB(2011)Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts Blood 118 282-288
[5]  
Spitzer TR(2013)Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies Biol Blood Marrow Transplant 19 1374-1380
[6]  
Ballen KK(2011)Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies JAMA 306 1874-1883
[7]  
Koreth J(2010)Relapse after allogeneic hematopoietic cell therapy Biol Blood Marrow Transplant 16 S138-S145
[8]  
Chen YB(2013)High-dose cytarabine (HD araC) in the treatment of leukemias: a review Curr Hematol Malignancy Rep 8 141-148
[9]  
Brunstein CG(2010)Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin Leukemia 24 467-469
[10]  
Fuchs EJ(2010)Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse Haematologica 95 1857-1864
12345678910